Celularity Presents Preclinical Data on Allogeneic Genetically-Modified Natural Killer Cells at the Society for Immunotherapy of Cancer 36th Annual Meeting

Rhea-AI Summary

Celularity Inc. (Nasdaq: CELU) presented preclinical data on its allogeneic NK cell therapy, CYNK-101, at the Society for Immunotherapy of Cancer Annual Meeting from November 10-14, 2021. CYNK-101, derived from genetically modified human placental CD34⁺ cells, demonstrated enhanced antibody-dependent cellular cytotoxicity against EGFR⁺ tumors when combined with Cetuximab. This research suggests potential applications in treating non-small cell lung cancer and head and neck cancers. Celularity aims to develop innovative therapies targeting unmet medical needs.

Positive

• CYNK-101 shows promise as an allogeneic NK cell therapy.
• Synergistic effect with Cetuximab could enhance cancer treatment efficacy.
• Focus on addressing significant unmet medical needs in cancer therapy.

Negative

• None.

FLORHAM PARK, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”) presented preclinical data on the development of its novel allogeneic genetically modified human placental CD34⁺ derived NK cell therapeutic program CYNK-101. Celularity reported its findings in a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting held in Washington, D.C., November 10-14, 2021.

Poster 159: “Developing placental CD34⁺-derived natural killer cells with high affinity cleavage resistant CD16 (CYNK-101) and Cetuximab for enhanced therapy of EGFR+ non-small cell lung and head and neck cancers”

Highlights: CYNK-101 is a cryopreserved off the shelf allogeneic NK cell product, overexpressing a high IgG binding affinity, proteinase cleavage resistant, CD16 variant. The results demonstrate the synergistic effect of combining CYNK-101 with Cetuximab to drive antibody dependent cellular cytotoxicity activity against EGFR⁺ tumors. Further development of the combinational therapy against EGFR⁺ non-small cell lung cancer and head and neck squamous cell carcinomas is warranted.

About Celularity

Celularity Inc. (Nasdaq: CELU) headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing allogeneic cryopreserved off-the-shelf placental-derived cell therapies, including therapeutic programs using unmodified natural killer (NK) cells, genetically modified NK cells, T-cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs). These therapeutic programs target indications in cancer, infectious and degenerative diseases. In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.

To learn more, visit celularity.com.

Celularity Investor Contacts:

Carlos Ramirez, SVP Investor Relations
Celularity
carlos.ramirez@celularity.com

Alexandra Roy
Solebury Trout
aroy@troutgroup.com

Celularity Media Contact:

Jason Braco, Ph.D.
LifeSci Communications
(646)-751-4361
jbraco@lifescicomms.com

FAQ

What is CYNK-101 and its significance for Celularity (CELU)?

CYNK-101 is an allogeneic NK cell therapy developed by Celularity, showing potential in treating EGFR+ tumors.

What were the results of the CYNK-101 presentation at the SITC Annual Meeting?

CYNK-101 demonstrated enhanced antibody-dependent cellular cytotoxicity when combined with Cetuximab.

What types of cancers might CYNK-101 target?

CYNK-101 may be effective against non-small cell lung cancer and head and neck cancers.

What is the next step for Celularity after presenting CYNK-101 data?

Celularity plans to further develop combinational therapies leveraging CYNK-101.